Viva Voce Examination: Vestibular Schwannoma Management
Viva Voce Examination: Vestibular Schwannoma Management
Question one: A forty-five-year-old patient is diagnosed with a unilateral vestibular schwannoma. Discuss the fundamental pathophysiology, including the genetic basis, common classifications relevant to anesthetic planning, and the implications of Neurofibromatosis Type two in this context.
Answer:
Vestibular schwannomas are benign, encapsulated tumors arising from the Schwann cells of the vestibulocochlear nerve, typically from its vestibular division. The vast majority, approximately ninety-five percent, are unilateral and sporadic. The core pathogenetic mechanism, for both sporadic and syndromic forms, involves the inactivation of the NFtwo gene located on chromosome twenty-two q twelve. This gene encodes for a tumor suppressor protein called merlin, or schwannomin. Loss of functional merlin disrupts normal cell growth regulation, leading to the proliferation of Schwann cells and tumor formation. While most vestibular schwannomas are sporadic, about five percent are associated with Neurofibromatosis Type two, an autosomal dominant condition characterized by the development of bilateral vestibular schwannomas.
The implications of Neurofibromatosis Type two for anesthetic management are profound. Neurofibromatosis Type two patients often present at a younger age, typically in the third decade, compared to the fourth to sixth decades for sporadic vestibular schwannomas. Beyond bilateral vestibular schwannomas, Neurofibromatosis Type two is a multisystem disorder associated with other central nervous system tumors such as meningiomas, spinal schwannomas, particularly in the Wishart type of Neurofibromatosis Type two, which presents earlier and is more severe, and ependymomas. They may also have juvenile posterior subcapsular cataracts and cutaneous schwannomas. This necessitates a more extensive pre-anesthetic workup, including a thorough neurological examination to identify other CNS lesions, spinal imaging if indicated, and assessment for potential end-organ dysfunction related to these associated conditions, for example, renal artery stenosis, pheochromocytoma, pulmonary fibrosis, cardiomyopathies, though these are less common than the CNS manifestations. Anesthetic plans must account for previous neurosurgeries, potential for increased intracranial pressure from multiple lesions, and the higher likelihood of cumulative neurological deficits impacting airway, respiratory, and cardiovascular function. The Manchester criteria are used for diagnosing Neurofibromatosis Type two. The presence of mosaic Neurofibromatosis Type two, resulting from postzygotic mutations, means some individuals may develop Neurofibromatosis Type two without a family history, with only a portion of their cells carrying the mutation.
For classification relevant to anesthetic planning, the Koos classification is paramount. This system grades vestibular schwannomas based on their size and extension:
Grade one: Small, purely intracanalicular tumor. Anesthetic focus is often on maximizing conditions for hearing preservation monitoring if attempted.
Grade two: Tumor protrudes into the cerebellopontine angle but does not contact the brainstem. Hearing preservation may still be a goal; risk to facial nerve increases slightly.
Grade three: Tumor occupies the cerebellopontine angle and contacts the brainstem but causes no displacement. Increased risk to facial and cochlear nerves; potential for mild brainstem effects.
Grade four: Large tumor causing displacement of the brainstem and adjacent cranial nerves. These tumors present significant anesthetic challenges, including a higher risk of preoperative hydrocephalus, intraoperative brainstem manipulation leading to hemodynamic instability, for example, trigeminocardiac reflex, difficult cranial nerve dissection, and significant postoperative neurological sequelae. Management of intracranial pressure and provision of a slack brain are critical. Understanding this classification allows the anesthesiologist to anticipate the surgical difficulty, potential for blood loss, duration of surgery, likelihood of cranial nerve involvement, and the need for specific monitoring and management strategies. Histopathologically, vestibular schwannomas typically shows Antoni A areas, hypercellular, spindle cells, Verocay bodies, S one hundred protein-positive and Antoni B areas, hypocellular, myxomatous. Cystic changes within the tumor can occur and may be associated with more rapid growth or different surgical outcome profiles.
Question two: Describe the classic and less common clinical manifestations of a vestibular schwannoma. How do these symptoms, and their sequence of appearance, aid in clinical localization and how might they influence your pre-anesthetic assessment, particularly concerning hydrocephalus?
Answer:
The clinical presentation of vestibular schwannoma is primarily dictated by the compression and dysfunction of the vestibulocochlear nerve and adjacent structures within the internal auditory canal and cerebellopontine angle.
The classic triad of symptoms includes two:
One. Unilateral Sensorineural Hearing Loss: This is the most common initial symptom, reported in eighty-five to ninety-five percent of patients. It is typically progressive, insidious in onset, and often affects high frequencies first. A key characteristic can be a disproportionate loss of speech discrimination relative to the pure tone audiometry thresholds, indicating retrocochlear pathology.
Two. Tinnitus: A ringing, buzzing, or hissing sound in the affected ear, present in approximately forty to sixty-five percent of patients. It can be constant or intermittent.
Three. Vestibular Dysfunction: This includes dysequilibrium, unsteadiness, or true vertigo, a sensation of spinning. While vertigo can occur, a more common complaint is a vague sense of imbalance, particularly with rapid head movements or when walking on uneven surfaces or in the dark. Frank, debilitating vertigo may be less common with very large tumors as the vestibular nerve function may be slowly and completely destroyed, allowing for central compensation. Interestingly, some studies suggest vertigo might be more prevalent in Koos Grade three tumors than Grade four, possibly due to ongoing irritation of a partially functional vestibular nerve before its complete destruction.
Less common manifestations, generally associated with larger tumors, for example, Koos Grade three or four, or atypical growth patterns, involve other cranial nerves and the brainstem or cerebellum:
Trigeminal Nerve Involvement: Facial numbness, paresthesia, or pain in the trigeminal distribution occurs in seventeen to forty-nine percent of cases, due to compression of the trigeminal nerve in the cerebellopontine angle. An absent corneal reflex may be found on examination.
Facial Nerve Involvement: Facial weakness or paresis is less common as an initial symptom, six to twenty-one percent, but its incidence increases with tumor size. Taste disturbances on the anterior two-thirds of the tongue can also occur. Significant facial weakness with a small tumor might suggest a more aggressive tumor or an unusual origin, such as an intralabyrinthine schwannoma with extension.
Lower Cranial Nerve Involvement: These are rare with vestibular schwannoma unless the tumor is very large and extends inferiorly, causing symptoms like dysphagia, hoarseness, or aspiration.
Cerebellar Compression: Leads to ataxia, dysmetria, and an unsteady gait, reported in up to forty-four point six percent of patients with large tumors.
Brainstem Compression: Can cause long tract signs, for example, pyramidal weakness, contralateral cranial nerve deficits, and nystagmus.
The sequence and combination of symptoms are crucial for localization. Early and predominant SNHL and tinnitus point to initial involvement within the IAC or at the porous acousticus. If facial numbness or trigeminal neuralgia precedes significant auditory symptoms, it might suggest a tumor with a more anterior or superior growth vector in the CPA, or even a primary trigeminal schwannoma. Early facial weakness is atypical for VS and warrants careful evaluation.
Hydrocephalus is a significant concern, particularly with larger tumors that compress the fourth ventricle, leading to obstructive hydrocephalus. Symptoms include headache (often worse in the morning), nausea, vomiting, lethargy, and papilledema. However, VS can also be associated with communicating hydrocephalus, even with smaller tumors that do not cause obvious CSF pathway obstruction. The proposed mechanism for this is an elevated CSF protein concentration, shed by the tumor, which impairs CSF resorption at the arachnoid granulations. This can manifest with symptoms of normal pressure hydrocephalus, including gait apraxia, cognitive decline, and urinary incontinence, especially in older individuals.
During pre-anesthetic assessment, specific inquiry about these symptoms is vital. An Evans ratio greater than zero point three on MRI is indicative of ventriculomegaly. The presence of hydrocephalus, whether obstructive or communicating, has major anesthetic implications:
· Increased baseline ICP, necessitating meticulous ICP management strategies.
· Potential need for preoperative CSF diversion (e.g., ventriculoperitoneal shunt or endoscopic third ventriculostomy, or an external ventricular drain).
· Increased risk of herniation with anesthetic induction or positive pressure ventilation if ICP is critically high.
· Altered cerebral autoregulation and compliance.
· Careful fluid management is required to avoid exacerbating cerebral edema. Thus, a detailed history of symptoms, correlated with imaging, is fundamental to anticipating and managing these complex physiological derangements.
Question three: Detail the primary diagnostic modalities for vestibular schwannoma. Explain the specific significance of advanced MRI sequences (e.g., CISS/FIESTA) and comprehensive audiological testing in pre-surgical planning and for predicting perioperative anesthetic challenges.
Answer:
The cornerstone of vestibular schwannoma diagnosis is Magnetic Resonance Imaging with gadolinium contrast. It is considered the gold standard, capable of detecting tumors as small as two millimeters. On T one-weighted images, VS typically appears isointense or hypointense, and on T two-weighted images, it is often hyperintense and heterogeneous. Following gadolinium administration, VS demonstrates avid, usually uniform enhancement. MRI accurately delineates tumor size, location (intracanalicular, cerebellopontine angle extension), relationship to the brainstem and cerebellum, presence of cystic components, and any associated hydrocephalus or displacement of the fourth ventricle. Cystic VS may be associated with more rapid growth and potentially different surgical outcomes, such as lower rates of complete resection and initially inferior facial nerve outcomes, though long-term outcomes may be similar to non-cystic tumors.
Advanced MRI sequences play a critical role in pre-surgical planning:
· High-resolution T two-weighted sequences, such as CISS (Constructive Interference in Steady State) or FIESTA (Fast Imaging Employing Steady-state Acquisition): These sequences provide excellent contrast between CSF (bright) and cranial nerves/tumor tissue (darker), allowing for precise visualization of the facial (CN seven) and cochlear nerves within the internal auditory canal and CPA. This is vital for:
o Surgical Planning: Delineating the course of the facial nerve relative to the tumor (e.g., displaced anteriorly, splayed over the capsule, or compressed). This information helps the surgeon anticipate the difficulty of dissection and strategize nerve preservation.
o Predicting IONM Needs: If the nerve is intimately involved with the tumor, the need for meticulous and reliable facial nerve monitoring (EMG) becomes even more critical, influencing anesthetic technique (e.g., preference for TIVA, strict avoidance of muscle relaxants during dissection).
o Prognostication: The degree of lateral IAC involvement by the tumor, as seen on these sequences, is known to adversely affect both facial nerve and hearing outcomes. This information helps in counseling the patient and setting realistic expectations.
Comprehensive audiological testing provides essential baseline functional information and complements imaging:
One. Pure Tone Audiometry (PTA): This is often the best initial screening test. It typically reveals an asymmetric sensorineural hearing loss, usually more pronounced at higher frequencies, on the affected side. The audiogram quantifies the degree of hearing loss.
Two. Speech Discrimination Score / Word Recognition Score: This assesses the patient's ability to understand speech. A hallmark of retrocochlear lesions like VS is often a disproportionately poor Speech Discrimination Score compared to the degree of pure tone hearing loss. This finding is highly suggestive of neural pathway dysfunction rather than just cochlear end-organ damage.
Three. Auditory Brainstem Response / Brainstem Evoked Response Audiometry: This electrophysiological test measures the neural activity along the auditory pathway from the cochlea to the brainstem in response to click stimuli. In VS, ABR typically shows delayed latencies (especially of Wave five, or prolonged I-V interpeak latency) or absent waveforms on the affected side, reflecting impaired neural conduction due to tumor compression.
o Significance for Anesthetic Planning: The baseline ABR is crucial if intraoperative BAEP monitoring is planned for hearing preservation attempts. It establishes the pre-existing neural integrity and serves as the reference against which intraoperative changes are judged. If baseline ABR is already significantly abnormal or absent, the utility or goals of intraoperative BAEP monitoring might be modified.
Other tests include:
· Vestibular Evoked Myogenic Potentials: Assess saccular (cVEMP via inferior vestibular nerve) and utricular (oVEMP via superior vestibular nerve) function. Abnormalities can help indicate which division of the vestibular nerve is primarily affected by the tumor, providing more precise localization of origin.
· Caloric Testing and Video Head Impulse Test: These assess peripheral vestibular function and typically show reduced or absent responses on the affected side.
Perioperative anesthetic challenges predicted by these modalities include:
· Difficult Nerve Dissection: Advanced MRI showing significant nerve displacement or encasement implies a longer, more meticulous surgery, with higher risk of nerve injury and greater reliance on IONM. This necessitates an anesthetic technique optimized for stable, high-quality IONM signals.
· Hearing Preservation Strategy: If audiology shows serviceable hearing and MRI suggests a favorable tumor anatomy, hearing preservation will be a surgical goal. This mandates intraoperative BAEP monitoring and an anesthetic that minimally interferes with it.
· Facial Nerve Risk: MRI and clinical assessment of facial nerve function will determine the anticipated risk. If high, facial nerve EMG and possibly MEP
monitoring will be paramount, strongly favoring TIVA and avoidance of neuromuscular blockade.
· Brainstem Involvement: Large tumors on MRI indicate potential brainstem compression, increasing risks of ICP issues, hemodynamic instability (TCR, cardiovascular center irritation), and need for careful brain relaxation techniques.
Computed Tomography has a limited role in primary vestibular schwannoma diagnosis but can be useful for assessing bony erosion of the internal auditory canal or associated hydrocephalus.
Question Four: Outline the essential components of a comprehensive pre-anesthetic neurological assessment for a patient scheduled for vestibular schwannoma resection via a retrosigmoid suboccipital approach. Emphasize the evaluation of cranial nerves Five, Seven, and the lower cranial nerves Nine, Ten, Twelve and the implications of any deficits.
Answer:
A comprehensive pre-anesthetic neurological assessment for a patient undergoing vestibular schwannoma resection via a retrosigmoid suboccipital approach is critical for risk stratification, planning intraoperative monitoring, and anticipating postoperative needs. The assessment should encompass:
One. History:
o Auditory Symptoms: Detailed history of onset, progression, and nature of hearing loss (unilateral, often high-frequency), tinnitus (character, laterality), and any sound recruitment or distortion.
o Vestibular Symptoms: Presence, frequency, and triggers of vertigo, dysequilibrium, imbalance (especially with quick turns or in low-light/uneven surfaces).
o Cranial Nerve Five (Trigeminal) Symptoms: Facial numbness, paresthesia, pain (distribution within Five One, Five Two, Five Three), or motor symptoms like difficulty chewing.
o Cranial Nerve Seven (Facial) Symptoms: Facial weakness (subtle or overt, e.g., difficulty closing eye, asymmetric smile), altered taste (anterior two-thirds of tongue), hyperacusis (stapedial reflex dysfunction).
o Lower Cranial Nerve (Nine, Ten, Twelve) Symptoms: Dysphagia (difficulty swallowing solids/liquids), dysphonia/hoarseness, nasal regurgitation, dysarthria, or history of aspiration. These are particularly important as deficits significantly increase postoperative aspiration risk.
Symptoms of Raised Intracranial Pressure or Hydrocephalus: Headache (character, timing, severity), nausea, vomiting (especially projectile), visual disturbances (diplopia, blurred vision), altered level of consciousness or cognitive changes.
o Cerebellar Symptoms: Gait ataxia, incoordination, clumsiness, intention tremor.
o General Neurological History: Seizures, previous neurosurgeries, family history of neurological disorders (especially neurofibromatosis Two). Patient's handedness should be noted.
Two. Physical Examination:
Two. Physical Examination:
o General: Level of consciousness (Glasgow Coma Scale), cognitive status, vital signs.
o Cranial Nerve Examination (Detailed):
. Cranial Nerve One (Olfactory): Usually not affected by vestibular schwannoma unless extremely large with anterior extension.
. Cranial Nerve Two (Optic): Visual acuity, visual fields, fundoscopy for papilledema (sign of raised intracranial pressure).
. Cranial Nerves Three, Four, Six (Oculomotor, Trochlear, Abducens): Extraocular movements, pupillary reflexes. Nystagmus may be present.
· Cranial Nerve Five (Trigeminal):
. Sensory: Test light touch, pinprick in all three divisions (Five One, Five Two, Five Three) bilaterally.
· Corneal Reflex: Afferent limb via Cranial Nerve Five One, efferent via Cranial Nerve Seven. An absent or diminished reflex is a significant finding.
· Motor: Palpate masseter and temporalis muscles during clenching, assess jaw deviation.
. Implications: Pre-existing Cranial Nerve Five deficit indicates tumor involvement and heightens awareness for intraoperative trigeminocardiac reflex during manipulation. Intraoperative monitoring of Cranial Nerve Five (masseter and temporalis electromyography) will be important.
· Cranial Nerve Seven (Facial):
· Inspect for facial asymmetry at rest and during voluntary movements (raising eyebrows, closing eyes tightly, smiling, puffing cheeks). Grade using House-Brackmann scale.
· Test taste on anterior two-thirds of tongue if symptoms suggest.
· Implications: Pre-existing Cranial Nerve Seven weakness worsens prognosis for postoperative facial function. It guides the intensity of facial nerve intraoperative monitoring and helps in preoperative counseling regarding potential outcomes.
· Cranial Nerve Eight (Vestibulocochlear):
. Auditory: Gross hearing assessment (finger rub, whispered voice). Weber and Rinne tests to confirm audiometric findings (sensorineural versus conductive loss).
· Vestibular: Observe for spontaneous or gaze-evoked nystagmus. Formal vestibular testing (calorics, video head impulse testing, vestibular evoked myogenic potentials) results should be reviewed.
· Implications: Baseline hearing status determines goals for hearing preservation and the need or interpretation of intraoperative brainstem auditory evoked potentials. Vestibular deficits guide preoperative counseling and planning for postoperative rehabilitation.
· Cranial Nerves Nine and Ten (Glossopharyngeal, Vagus):
· Assess gag reflex (afferent Nine, efferent Ten).
· Observe palatal elevation (uvula deviation away from side of lesion with Cranial Nerve Ten palsy).
. Assess voice quality (hoarseness may indicate Cranial Nerve Ten palsy).
· Inquire about swallowing difficulties.
· Implications: Pre-existing deficits in Cranial Nerves Nine and Ten are critical flags for increased risk of postoperative aspiration, dysphagia, and airway compromise. This may necessitate a modified anesthetic emergence, delayed extubation, early speech and swallow assessment post-operative, and potentially alternative nutritional routes.
. Cranial Nerve Eleven (Accessory): Test sternocleidomastoideopezius muscle strength.
. Cranial Nerve Twelve (Hypoglossal): Inspect tongue for fasciculations or atrophy. Test tongue protrusion (deviates towards side of lesion).
· Implications: Cranial Nerve Twelve deficits, often in conjunction with Nine and Ten, further compound swallowing and speech problems. Cerebellar Function: Finger-nose test, heel-shin test, rapid alternating movements, assessment of gait (tandem gait, Romberg test).
o Motor and Sensory System: Assess limb strength, tone, reflexes, and sensation to detect any long tract signs from brainstem compression.
A meticulous neurological baseline is indispensable. It allows for identification of patients at higher risk for specific intraoperative events (e.g., trigeminocardiac reflex with Cranial Nerve Five involvement) and postoperative complications (e.g., aspiration with lower Cranial Nerve palsies), informs the intraoperative monitoring strategy, aids in patient counseling, and serves as the crucial reference against which any postoperative changes are measured.
Question Five: A patient with a Koos Grade Four vestibular schwannoma presents for pre-anesthetic evaluation. Discuss the specific systemic co-morbidities you would screen for and optimize, and how the presence of brainstem compression or hydrocephalus might influence your anesthetic risk stratification and preoperative preparation.
Answer:
A Koos Grade Four vestibular schwannoma, by definition, is a large tumor causing displacement of the brainstem and cranial nerves. This has significant implications for both neurological status and systemic physiology, necessitating a thorough pre-anesthetic evaluation focused on co-morbidities and the direct effects of the tumor.